Contact Us Site Map

REL-EASE™ Drug Delivery Technology

We have developed Rel-Ease™, our proprietary sustained release drug delivery technology, to allow for the delivery of drugs in an injectable long-acting depot and potentially in oral formulations. For example, using Rel-Ease™ technology, we are able to formulate Plenaxis® in such a way that a physician needs to administer it to prostate cancer patients only once every four weeks (following the first month, in which an additional dose is given on day 15). In addition to the obvious benefit of reducing the frequency of dosing for injectable drugs, less frequent injections of a drug in a sustained release formulation may also be more advantageous and desirable than oral administration, leading to improved patient compliance, added convenience and/or simplified reimbursement.